- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01608620
Meta-analyses of Total and Individual Fructose-containing Sugars and Incident Cardiometabolic Disease
The Relation of Total and Individual Fructose-containing Sugars With Incident Cardiometabolic Diseases: A Series of Systematic Reviews and Meta-analyses of Prospective Observational Studies
Study Overview
Status
Detailed Description
Background: Fructose has become a focus of intense concern regarding its links to the obesity epidemic and increasing burden of cardiometabolic disease. There have been dozens of editorials, commentaries, and letters in the scientific literature and numerous pieces in the lay and social media calling for efforts to restrict its intake and even regulate it like tobacco or alcohol. Uncontrolled ecological analyses which have linked increasing fructose intake with increasing obesity, diabetes, and hypertension rates and animal models of fructose induced metabolic syndrome and hypertension, which overfeed fructose at levels of exposure far beyond actual population levels of intake, have been used to underpin this debate. Evidence from well-adjusted prospective cohort studies also suggest a positive association between the consumption of sugar-sweetened beverages and increased energy consumption and weight gain. But not all meta-analyses of the available prospective cohort studies have supported this conclusion for SSBs, and no meta-analyses have investigated the effect of total fructose-containing sugars which also include grain and fruit sources on incident overweight/obesity, diabetes, metabolic syndrome, hypertension, gout, and cardiovascular disease. Despite the limitations in extrapolating from the available observational data and their inconsistency with data from controlled trials in humans (the highest level of evidence used in evidence based medicine) which do not show any adverse metabolic effects under isocaloric feeding conditions, the heart and diabetes associations have taken a risk reduction approach to added fructose-containing sugars, setting highly restrictive upper thresholds for their intake to achieve and maintain healthy body-weights and avoid adverse lipid effects.
Objective: To improve the evidence on which recommendations and public health policy are based, we will conduct a series of systematic reviews and meta-analyses of the role of fructose-containing sugars in the development of cardiometabolic disease in prospective cohort studies. A total of 5 analyses are proposed: (1)overweight/obesity, (2) diabetes/metabolic syndrome, (3) hypertension, (4) gout, and (5) coronary heart disease (CHD).
Design: The planning and conduct of the proposed meta-analyses will follow the Cochrane handbook for systematic reviews of interventions. The reporting will follow the Meta-analysis Of Observational Studies in Epidemiology (MOOSE) guidelines.
Data sources. MEDLINE, EMBASE, CINAHL and The Cochrane Central Register of Controlled Trials (Clinical Trials; CENTRAL) will be searched using appropriate search terms, supplemented by manual, hand searches of bibliographies.
Study selection: We will include prospective cohort studies investigating the relation of fructose-containing (fructose, sucrose, and HFCS) sugars to incident overweight/obesity, diabetes, metabolic syndrome, hypertension, gout, and cardiovascular disease.
Data extraction. Two investigators will independently extract information about study design, sample size, subject characteristics, fructose form, fructose exposure levels, duration/person-years of follow-up, background diet profile, adjustments of models. Risk ratios for clinical outcomes will be extracted or derived from clinical event data across quantiles of exposure. Risk of bias will be assessed using the Cochrane Risk of Bias tool.
Outcomes: Each of the 5 proposed analyses will assess a different cardiometabolic disease outcome: (1) overweight/obesity, (2) diabetes/metabolic syndrome, (3) hypertension, (4) gout, and (5) CHD.
Data synthesis. The natural log-transformed relative risks of clinical outcomes comparing the highest exposure level to the reference group from each cohort will be pooled using the generic inverse variance method with random effects models. Heterogeneity will be assessed by Cochrane's Q and quantified by I2. Sensitivity analyses and a priori subgroup analyses will be undertaken to explore sources of heterogeneity including the effect of underlying disease status, sex, sugar type (fructose, sucrose, HFCS), follow-up (<10-years, >=10-years), level of adjustment of models, and Cochrane risk of bias on the effect of fructose. Significant unexplained heterogeneity will be investigated by additional post hoc subgroup analyses. Meta-regression analyses will assess the significance of subgroups analyses. Dose-response analyses will be undertaken using random-effects generalized least squares trend estimation models (GLST), appropriate for weighted regression of summarized dose-response data with dependent components(i.e. the reference exposure level). If insufficient evidence of a linear relationship is found, then we will do spline curve modeling (the MKSPLINE procedure) to characterize segments of the dose response curve where a linear approximation best describes the data. Publication bias will be assessed by the inspection of funnel plots and using Begg's and Egger's tests.
Knowledge translation plan: The results will be disseminated through interactive presentations at local, national, and international scientific meetings and publication in high impact factor journals. Target audiences will include the public health and scientific communities with interest in nutrition, diabetes, obesity, and cardiovascular disease. Feedback will be incorporated and used to improve the public health message and key areas for future research will be defined. Applicant/Co-applicant Decision Makers will network among opinion leaders to increase awareness and participate directly as committee members in the development of future guidelines.
Preliminary findings: To address the uncertainties in the evidence, we conducted a series of Canadian Institutes of Health Research (CIHR) funded systematic reviews and meta-analyses of controlled feeding trials of the effect of fructose on cardiometabolic risk (ClinicalTrials.gov registration number: NCT01363791). We found that fructose in isocaloric substitution for other sources of carbohydrate (isocaloric trials) does not increase body weight, lipids, blood pressure, uric acid, or insulin and even improves glycemic control. There was, however, a signal for harm under certain conditions. High doses of fructose increased triglycerides in isocaloric trials, and fructose providing excess energy at extreme doses relative to control diets (hypercaloric trials) also increased body weight, triglycerides, and uric acid. The implications of these findings for "real world" dietary advice, however, were complicated by several factors. First, fructose is not commonly consumed in isolation as a sweetener. Sucrose and HFCS are the primary fructose-containing sweeteners in the U.S. diet. Second, the level of fructose exposure in the available trials was well above population levels of intake, exceeding the 95th-percentile for U.S. intake in most of the isocaloric trials and in all of the hypercaloric trials, in which the excess energy brought by fructose was an important source of confounding. Finally, the available trials investigated effects on biomarkers of disease and not clinically meaningful events. The proposed systematic review and meta-analyses of prospective cohort studies will address these limitations directly by investigating the relation of self-reported, "real world" intakes of all fructose-containing sugars (fructose, sucrose, and HFCS) to the development overweight/obesity, diabetes/metabolic syndrome, hypertension, gout, and cardiovascular disease.
Significance: The proposed project will aid in knowledge translation related to the effects of dietary fructose on overweight/obesity, diabetes/metabolic syndrome, hypertension, gout, and cardiovascular disease, strengthening the evidence-base for recommendations and improving health outcomes through informing consumers and guiding future research.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M5C 2T2
- The Toronto 3D (Diet, Digestive tract and Disease) Knowledge Synthesis and Clinical Trials Unit, Clinical Nutrition and Risk Factor Modification Centre, St. Michael's Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Prospective observational studies
- Assessment of fructose-containing sugar exposure
- Viable clinical outcome data by level of exposure
Exclusion Criteria:
- Ecological, cross-sectional, and retrospective observational studies, clinical trials, and non-human studies
- No assessment of fructose-containing sugar exposure
- No viable clinical outcome data by level of exposure
Study Plan
How is the study designed?
Design Details
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overweight/obesity analysis
Time Frame: up to 1.5-years
|
Risk ratios for incident Overweight and obesity by total fructose-containing sugar exposure
|
up to 1.5-years
|
Diabetes/metabolic syndrome analysis
Time Frame: Up to 1.5-years
|
Risk ratios for incident diabetes and metabolic syndrome by total fructose-containing sugar exposure
|
Up to 1.5-years
|
Hypertension analsysis
Time Frame: Up to 1.5-years
|
Risk ratios for incident hypertension by total fructose-containing sugar exposure
|
Up to 1.5-years
|
Gout analysis
Time Frame: Up to 1.5-years
|
Risk ratios for incident gout by total fructose-containing sugar exposure
|
Up to 1.5-years
|
Coronary heart disease (CHD) analysis
Time Frame: Up to 1.5-years
|
Risk ratios for incident CHD by total fructose-containing sugar exposure
|
Up to 1.5-years
|
Collaborators and Investigators
Publications and helpful links
General Publications
- Sievenpiper JL, Carleton AJ, Chatha S, Jiang HY, de Souza RJ, Beyene J, Kendall CW, Jenkins DJ. Heterogeneous effects of fructose on blood lipids in individuals with type 2 diabetes: systematic review and meta-analysis of experimental trials in humans. Diabetes Care. 2009 Oct;32(10):1930-7. doi: 10.2337/dc09-0619. Epub 2009 Jul 10.
- Sievenpiper JL, de Souza RJ, Mirrahimi A, Yu ME, Carleton AJ, Beyene J, Chiavaroli L, Di Buono M, Jenkins AL, Leiter LA, Wolever TM, Kendall CW, Jenkins DJ. Effect of fructose on body weight in controlled feeding trials: a systematic review and meta-analysis. Ann Intern Med. 2012 Feb 21;156(4):291-304. doi: 10.7326/0003-4819-156-4-201202210-00007.
- Sievenpiper JL, Chiavaroli L, de Souza RJ, Mirrahimi A, Cozma AI, Ha V, Wang DD, Yu ME, Carleton AJ, Beyene J, Di Buono M, Jenkins AL, Leiter LA, Wolever TM, Kendall CW, Jenkins DJ. 'Catalytic' doses of fructose may benefit glycaemic control without harming cardiometabolic risk factors: a small meta-analysis of randomised controlled feeding trials. Br J Nutr. 2012 Aug;108(3):418-23. doi: 10.1017/S000711451200013X. Epub 2012 Feb 21.
- Ha V, Sievenpiper JL, de Souza RJ, Chiavaroli L, Wang DD, Cozma AI, Mirrahimi A, Yu ME, Carleton AJ, Dibuono M, Jenkins AL, Leiter LA, Wolever TM, Beyene J, Kendall CW, Jenkins DJ. Effect of fructose on blood pressure: a systematic review and meta-analysis of controlled feeding trials. Hypertension. 2012 Apr;59(4):787-95. doi: 10.1161/HYPERTENSIONAHA.111.182311. Epub 2012 Feb 13.
- Wang DD, Sievenpiper JL, de Souza RJ, Chiavaroli L, Ha V, Cozma AI, Mirrahimi A, Yu ME, Carleton AJ, Di Buono M, Jenkins AL, Leiter LA, Wolever TM, Beyene J, Kendall CW, Jenkins DJ. The effects of fructose intake on serum uric acid vary among controlled dietary trials. J Nutr. 2012 May;142(5):916-23. doi: 10.3945/jn.111.151951. Epub 2012 Mar 28.
- Sievenpiper JL, de Souza RJ, Jenkins DJ. Sugar: fruit fructose is still healthy. Nature. 2012 Feb 22;482(7386):470. doi: 10.1038/482470e. No abstract available. Erratum In: Nature. 2012 Mar 22;483(7390):407.
- Sievenpiper JL, de Souza RJ, Kendall CW, Jenkins DJ. Is fructose a story of mice but not men? J Am Diet Assoc. 2011 Feb;111(2):219-20; author reply 220-2. doi: 10.1016/j.jada.2010.12.001. No abstract available.
- Jayalath VH, Sievenpiper JL, de Souza RJ, Ha V, Mirrahimi A, Santaren ID, Blanco Mejia S, Di Buono M, Jenkins AL, Leiter LA, Wolever TM, Beyene J, Kendall CW, Jenkins DJ. Total fructose intake and risk of hypertension: a systematic review and meta-analysis of prospective cohorts. J Am Coll Nutr. 2014;33(4):328-39. doi: 10.1080/07315724.2014.916237. Epub 2014 Aug 21.
- Khan TA, Tayyiba M, Agarwal A, Mejia SB, de Souza RJ, Wolever TMS, Leiter LA, Kendall CWC, Jenkins DJA, Sievenpiper JL. Relation of Total Sugars, Sucrose, Fructose, and Added Sugars With the Risk of Cardiovascular Disease: A Systematic Review and Dose-Response Meta-analysis of Prospective Cohort Studies. Mayo Clin Proc. 2019 Dec;94(12):2399-2414. doi: 10.1016/j.mayocp.2019.05.034.
- Tsilas CS, de Souza RJ, Mejia SB, Mirrahimi A, Cozma AI, Jayalath VH, Ha V, Tawfik R, Di Buono M, Jenkins AL, Leiter LA, Wolever TMS, Beyene J, Khan T, Kendall CWC, Jenkins DJA, Sievenpiper JL. Relation of total sugars, fructose and sucrose with incident type 2 diabetes: a systematic review and meta-analysis of prospective cohort studies. CMAJ. 2017 May 23;189(20):E711-E720. doi: 10.1503/cmaj.160706.
- Jamnik J, Rehman S, Blanco Mejia S, de Souza RJ, Khan TA, Leiter LA, Wolever TM, Kendall CW, Jenkins DJ, Sievenpiper JL. Fructose intake and risk of gout and hyperuricemia: a systematic review and meta-analysis of prospective cohort studies. BMJ Open. 2016 Oct 3;6(10):e013191. doi: 10.1136/bmjopen-2016-013191.
- Jayalath VH, de Souza RJ, Ha V, Mirrahimi A, Blanco-Mejia S, Di Buono M, Jenkins AL, Leiter LA, Wolever TM, Beyene J, Kendall CW, Jenkins DJ, Sievenpiper JL. Sugar-sweetened beverage consumption and incident hypertension: a systematic review and meta-analysis of prospective cohorts. Am J Clin Nutr. 2015 Oct;102(4):914-21. doi: 10.3945/ajcn.115.107243. Epub 2015 Aug 12.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
- Insulin resistance
- Cholesterol
- Fructose
- Blood pressure
- Uric acid
- Fruit
- Evidence-based nutrition (EBN)
- Body weight
- Triglycerides
- Systematic review and meta-analysis
- Evidence-based medicine (EBM)
- Clinical practice guidelines
- Clinical trials
- Dietary sugars
- High fructose corn syrup
- Isocaloric
- Hypercaloric
- Glycemic control
- Cardiometabolic risk factors
Additional Relevant MeSH Terms
- Vascular Diseases
- Glucose Metabolism Disorders
- Metabolic Diseases
- Arteriosclerosis
- Arterial Occlusive Diseases
- Body Weight
- Insulin Resistance
- Hyperinsulinism
- Lipid Metabolism Disorders
- Heart Diseases
- Coronary Artery Disease
- Myocardial Ischemia
- Coronary Disease
- Cardiovascular Diseases
- Metabolic Syndrome
- Dyslipidemias
- Overweight
- Hyperlipidemias
Other Study ID Numbers
- CCC-Sugars epi 2012
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertension
-
National Taiwan University Hospital Hsin-Chu BranchRecruitingHypertension,Essential | Hypertension, MaskedTaiwan
-
University of Alabama at BirminghamTroy UniversityCompletedHypertension | Hypertension, Resistant to Conventional Therapy | Uncontrolled Hypertension | Hypertension, White CoatUnited States
-
BayerCompletedPrimary HypertensionChina
-
Addpharma Inc.Completed
-
Columbia UniversityAgency for Healthcare Research and Quality (AHRQ)Active, not recruitingWhite Coat Hypertension | Hypertension,EssentialUnited States
-
Universidade Federal de Santa MariaCompletedHealthy Volunteers | Hypertension, EssentialBrazil
-
Sulaiman AlRajhi CollegesUnknownHypertension, Essential | β-hydroxybutyrate
-
Centre Chirurgical Marie LannelongueUnknownChronic Thrombo-embolic Pulmonary Hypertension and Pulmonary Arterial HypertensionFrance
-
Sheffield Teaching Hospitals NHS Foundation TrustUniversity of SheffieldCompletedIdiopathic Pulmonary Arterial Hypertension | Chronic Thromboembolic Pulmonary HypertensionUnited Kingdom